Amygdalin Modulates Prostate Cancer Cell Adhesion and Migration In Vitro

References

• Siegel R, Naishadham D, and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63, 11–30, 2013.
   PubMed Web of Science ®Google Scholar
• Grubb RL, 3rd, and Kibel AS: Prostate cancer: screening, diagnosis and management in 2007. Mo Med 104, 408–413, 2007.
   PubMedGoogle Scholar
• Feldman BJ, and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34–45, 2001.
   PubMed Web of Science ®Google Scholar
• Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. JCO 32, 3436–3448, 2014.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ: New treatment options in castration-resistant prostate cancer. J Natl Compr Canc Netw 13, 690–693, 2015.
   PubMed Web of Science ®Google Scholar
• Gupta E, Guthrie T, and Tan W: Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol 14, 55, 2014.
   PubMed Web of Science ®Google Scholar
• Bishop FL, Rea A, Lewith H, Chan YK, Saville J, et al. Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. Prostate Cancer Prostatic Dis 14, 1–13, 2011.
   PubMed Web of Science ®Google Scholar
• Hierl M, Pfirstinger J, Andreesen R, Holler E, Mayer S, et al. Complementary and alternative medicine: a clinical study in 1,016 hematology/oncology patients. Oncology 93, 157–163, 2017.
   PubMed Web of Science ®Google Scholar
• Schieman C, Rudmik LR, Dixon E, Sutherland F, and Bathe OF: Complementary and alternative medicine use among general surgery, hepatobiliary surgery and surgical oncology patients. Can J Surg 52, 422–426, 2009.
   PubMed Web of Science ®Google Scholar
• Miller MC, Pribitkin EA, Difabio T, and Keane WM: Prevalence of complementary and alternative medicine use among a population of head and neck cancer patients: a survey-based study. Ear Nose Throat J 89, E23–E27, 2010.
   PubMedGoogle Scholar
• Blaheta RA, Nelson K, Haferkamp A, and Juengel E: Amygdalin, quackery or cure? Phytomedicine 23, 367–376, 2016.
   PubMed Web of Science ®Google Scholar
• BfArM 2014: Werbung für bedenkliche Arzneimittel, hier: Amygdalin. Available at: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Gremien/RoutinesitzungPar63AMG/74Sitzung/pkt-4-3.pdf?__blob=publicationFile&v=2 (Accessed April 30, 2018).
   Google Scholar
• Makarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, et al. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci 147, 137–142, 2016.
   PubMed Web of Science ®Google Scholar
• Juengel E, Meyer dos Santos S, Schneider T, Makarević J, Hudak L, et al. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. Exp Biol Med (Maywood) 238, 1297–1304, 2013.
   PubMed Web of Science ®Google Scholar
• Makarević J, Rutz J, Juengel E, Kaulfuss S, Tsaur I, et al. Amygdalin influences bladder cancer cell adhesion and invasion in vitro. PLoS One 9, e110244, 2014.
   PubMed Web of Science ®Google Scholar
• Chang HK, Shin MS, Yang HY, Lee JW, Kim YS, et al. Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull 29, 1597–1602, 2006.
   PubMed Web of Science ®Google Scholar
• Chin SP, Marthick JR, West AC, Short AK, Chuckowree J, et al. Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer. Prostate 75, 723–734, 2015.
   PubMed Web of Science ®Google Scholar
• Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, et al. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 28, 479–491, 2011.
   PubMed Web of Science ®Google Scholar
• Lityńska A, Przybyło M, Pocheć E, and Laidler P: Adhesion properties of human bladder cell lines with extracellular matrix components: the role of integrins and glycosylation. Acta Biochim Pol 49, 643–650, 2002.
   PubMed Web of Science ®Google Scholar
• Juengel E, Afschar M, Makarević J, Rutz J, Tsaur I, et al. Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism. Int J Mol Med 37, 843–850, 2016.
   PubMed Web of Science ®Google Scholar
• Neal CL, Mckeithen D, and Odero-Marah VA: Snail negatively regulates cell adhesion to extracellular matrix and integrin expression via the MAPK pathway in prostate cancer cells. Cell Adh Migr 5, 249–257, 2011.
   PubMed Web of Science ®Google Scholar
• Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O’Rear LD, et al. The α2β1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 121, 226–237, 2011.
   PubMed Web of Science ®Google Scholar
• Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, et al. Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis 30, 569–578, 2013.
   PubMed Web of Science ®Google Scholar
• Berg K, Lange T, Mittelberger F, Schumacher U, and Hahn U: Selection and characterization of an α6β4 integrin blocking DNA aptamer. Mol Ther Nucleic Acids 5, e294, 2016.
   PubMedGoogle Scholar
• Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, et al. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6-Integrin expression. Cancer Res 75, 2326–2336, 2015.
   PubMed Web of Science ®Google Scholar
• Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, et al. Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13, 1558–1566, 2014.
   PubMed Web of Science ®Google Scholar
• Pan B, Guo J, Liao Q, and Zhao Y: β1 and β3 integrins in breast, prostate and pancreatic cancer: a novel implication. Oncol Lett 15, 5412–5416, 2018.
   PubMed Web of Science ®Google Scholar
• Oszajca K, Bieniasz M, Brown G, Swiatkowska M, Bartkowiak J, et al. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells. Biochem Cell Biol 86, 477–486, 2008.
   PubMed Web of Science ®Google Scholar
• Ferraris GM, Schulte C, Buttiglione V, De Lorenzi V, Piontini A, et al. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins. Embo J 33, 2458–2472, 2014.
   PubMed Web of Science ®Google Scholar
• Zhuang T, Chelluboina B, Ponnala S, Velpula KK, Rehman AA, et al. Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC Cancer 13, 590, 2013.
   PubMed Web of Science ®Google Scholar
• Qian L, Xie B, Wang Y, and Qian J: Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int J Clin Exp Pathol 8, 5363–5370, 2015.
   PubMed Web of Science ®Google Scholar
• Lin CH, Lin HH, Kuo CY, and Kao SH: Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling. Oncotarget 8, 11316–11328, 2017.
   PubMedGoogle Scholar
• Kanno Y, Ishisaki A, Miyashita M, and Matsuo O: The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin β3/Akt pathway. Immun Inflamm Dis 4, 338–349, 2016.
   PubMed Web of Science ®Google Scholar
• Cunningham D, and You Z: In vitro and in vivo model systems used in prostate cancer research. J Biol Methods 2, 17, 2015.
   PubMedGoogle Scholar
• Fontana F, Raimondi M, Marzagalli M, Sommariva M, Limonta P, et al. Epithelial-to-mesenchymal transition markers and CD44 isoforms are differently expressed in 2D and 3D cell cultures of prostate cancer cells. Cells 8, 143, 2019.
   Web of Science ®Google Scholar
• Ariyoshi-Kishino K, Hashimoto K, Amano O, Saitoh J, Kochi M, et al. Tumor-specific cytotoxicity and type of cell death induced by benzaldehyde. Anticancer Res 30, 5069–5076, 2010.
   PubMed Web of Science ®Google Scholar